Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 374 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eyes With Glaucoma Clear all
Terminated Not applicable Interventional Results available

Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus

NCT03560609
View directory record Official record
Conditions
Keratoconus, Glaucoma
Interventions
Ophthalmodynamometer, Goldmann applanation tonometer, Pentacam, ORA, Optical Coherence Tomography (OCT)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106
View directory record Official record
Conditions
Glaucoma, Angle-closure, Primary, Acute
Interventions
QPI-1007 Injection, (including placebo)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Orange, California • Pasadena, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT03488550
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
ANX007
Biological
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

NCT01001195
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2013 · Synced Oct 22, 2026, 1:53 AM EDT
Not yet recruiting Not applicable Interventional

Direct Selective Laser Trabeculoplasty (DSLT) for Patients With Glaucoma or Ocular Hypertension Previously Treated With SLT

NCT07589270
View directory record Official record
Conditions
Ocular Hypertension Glaucoma, POAG
Interventions
DSLT
Device
Lead sponsor
The New York Eye Surgery Center
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 1:53 AM EDT
Terminated Not applicable Interventional Results available

A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

NCT04616573
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System, iStent inject
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Dothan, Alabama • Vineland, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

NCT04629521
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Cataract
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT02531152
View directory record Official record
Conditions
Open Angle Glaucoma -Ocular Hypertension
Interventions
Latanoprost, SAR366234
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Inglewood, California • Cape Coral, Florida • Roswell, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 22, 2026, 1:53 AM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

NCT03891446
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, Standard of Care
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
66
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 1:53 AM EDT
Not listed Phase 2 Interventional

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 22, 2026, 1:53 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

NCT06369077
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions
dorzolamide/timolol
Drug
Lead sponsor
CT Glaucoma Associates
Other
Eligibility
25 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 22, 2026, 1:53 AM EDT
Not listed Not applicable Interventional

Effects of Xal-Ease on Patient Compliance With Xalatan

NCT00573638
View directory record Official record
Conditions
Glaucoma
Interventions
Xal-Ease device to be used with Xalatan eye drops
Device
Lead sponsor
Augusta University
Other
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Oct 22, 2026, 1:53 AM EDT
Terminated Not applicable Interventional Results available

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

NCT05273385
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Open Angle Glaucoma
Interventions
Nanodropper
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 1:53 AM EDT
Recruiting Not applicable Interventional

Glaucoma Laser Assessment of Stability and Sustainability

NCT06963684
View directory record Official record
Conditions
Glaucoma
Interventions
Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Twin Cities Eye Consultants
Other
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Coon Rapids, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

InnFocus MicroShunt Versus Trabeculectomy Study

NCT01881425
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Glaucoma Surgery, InnFocus MicroShunt
Procedure · Device
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00652106
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT01177098
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 22, 2026, 1:53 AM EDT
Recruiting No phase listed Observational

Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

NCT06953349
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
Procedure
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT04445519
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial)
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

NCT01895972
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprostene bunod
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
20 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 22, 2026, 1:53 AM EDT
Completed No phase listed Observational

Potential Research Participants for Future Studies of Inherited Eye Diseases

NCT00559234
View directory record Official record
Conditions
Cataract, Glaucoma, Retinitis Pigmentosa, Macular Degeneration, Strabismus
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 1:53 AM EDT